Diazafluorenone il-8 antagonists

The present invention relates to diazafluorenone derivatives of Formula I which are IL-8 receptor antagonists useful as pharmaceutical agents, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to methods of treating a chemokine-mediated disease state in a mammal, including a human. The diazafluorenones of the present invention are useful in the treatment of chemokine-mediated diseases such as, psoriasis, cancer, asthma, Alzheimer's disease, inflammatory bowel disease, graft versus host reaction, or allograft rejections in a mammal, including a human.